The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
Chat on the emotional side of healing
The Emotional Side of Healing was the subject of ABC News National Health’s weekly Twitter chat this past week, and patients, caregivers and clinicians were all asked to weigh-in on this area of interest. VCU Massey Cancer Center’s Egidio Del Fabbro, M.D., program director of palliative care, and Danielle Noreika, M.D., medical director of inpatient palliative care services, provided expert commentary as the moderator posed a series of questions and discussion topics.
Massey research leads to multi-institutional phase 1 clinical trial for relapsed/refractory aggressive lymphomas
Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., is the co-principal investigator (PI) on a National Comprehensive Cancer Network (NCCN) grant funding a phase 1 clinical trial testing the drugs volasertib and belinostat in patients with relapsed and refractory aggressive B-cell and T-cell lymphomas. The $453,852 award will help implement the clinical trial at Massey, Yale Comprehensive Cancer Center and Johns Hopkins’ Sidney Kimmel Comprehensive Cancer Center.
Massey investigator selected for the Lymphoma Research Foundation’s Clinical Research Mentoring Program
The Lymphoma Research Foundation (LRF) has accepted VCU Massey Cancer Center researcher Victor Yazbeck, M.D., into its Clinical Research Mentoring Program (CRMP). The CRMP is a two-year program that selects up-and-coming lymphoma researchers to participate in educational courses, laboratory work and clinical studies in order to further their own research goals.
Massey scientists contribute to research involving the latest FDA-approved cancer therapies
VCU Massey Cancer Center doctors and scientists are making important discoveries involving cancer-fighting drugs recently approved by the U.S. Food and Drug Administration (FDA). Between August 2013 and July 2014, the FDA approved six new anticancer therapeutics, five of which target the unique molecular and genetic characteristics of an individual’s cancer.
As President Obama proposes national investment in precision medicine research, Massey leads the way in Virginia
President Obama recently proposed a major Precision Medicine Initiative that allocates $215 million in the federal 2016 budget for precision medicine research. Designated by the National Cancer Institute (NCI) to lead and shape the nation’s fight against cancer, Virginia Commonwealth University Massey Cancer Center has already taken steps to bring the benefits of precision medicine to Virginia. Of the President’s $215 million proposed investment, $70 million will be provided to the NCI to scale up efforts to identify the genomic drivers in cancer and to translate this information into more effective strategies to prevent and treat cancer.